title: mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer.
abstract: Among currently available vaccine strategies for cancer, nucleotide-based vaccination is an appealing treatment modality. Curevacs' mRNA containing vaccines (RNActive®) combine the beneficial properties of sufficient antigen-expression, autologous immune-stimulation and a high flexibility with respect to production and application. CV9103 and CV9104 are novel RNActive®-derived anticancer vaccines for the treatment of patients with prostate cancer. After successful phase I/II studies with documentation of good tolerability and favorable immune-activation of CV9103, the vaccine CV9104 is currently undergoing clinical testing in specific clinical settings such as castration resistant prostate cancer and as a neoadjuvant agent in men with high risk prostate cancer prior to surgery. This review discusses the available preclinical and clinical data on the anticancer vaccination treatment with RNActive®-derived anticancer-vaccines CV9103 and CV9104.
authors.affiliation: a Department of Urology ; Eberhard Karls University Tübingen ; Tübingen , Germany.
authors.forename: Steffen
authors.initials: S
authors.lastname: Rausch
authors.forename: Christian
authors.initials: C
authors.lastname: Schwentner
authors.forename: Arnulf
authors.initials: A
authors.lastname: Stenzl
authors.forename: Jens
authors.initials: J
authors.lastname: Bedke
mesh_terms: D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000276:immunology / Q000628:therapy*; D012333:RNA, Messenger / Q000276:immunology / Q000627:therapeutic use*; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D019496:Cancer Vaccines; D012333:RNA, Messenger; D014614:Vaccines, Synthetic
keywords: CRPC; RNActive; immunotherapy; mRNA; metastatic; prostate cancer; vaccination